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ABSTRACT 
Objective: The aim of the present meta-analysis study is to investigate whether human papillomavirus (HPV) serves as a cause or as the cause of human 
prostate cancer (PC).    
Methods: The PubMed database was searched for suitable articles. Previously published expert reviews and systematic meta-analysis were used as an 
additional source to identify appropriate articles. Articles selected for this meta-analysis should fulfill the following inclusion criteria: (a) no data access 
barrier, (b) polymerase chain reaction (PCR) DNA based identification of HPV. The method of the conditio sine qua non relatio nship was used to prove the 
hypotheses whether being married is a necessary condition (a conditio sine qua non) of PC. In other words, without being married no PC. The method of the 
conditio per quam relationship (sufficient condition) was used to prove the hypotheses if HPV is present in human prostate tissues then PC is present too. 
The mathematical formula of the causal relationship k was used to prove the hypothesis, whether there is a cause effect relationship betw een HPV and PC. 
Significance was indicated by a p-value (two sided) of less than 0.05.  
Results: In to more than 33 studies were considered for a meta-analysis. Several studies support the hypotheses without being married no PC. All the 
studies considered for a re-analysis support the null-hypotheses if HPV then PC, while the cause effect relationship between HPV and PC was highly 
significant.  
Conclusions: HPV is the cause of PC. 
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INTRODUCTION 
Human1 papilloma2 virus3 (HPV) is a small DNA4 virus and 
responsible for several benign and malignant diseases. More than 
200 types5 of HPV have been identified to date. Meanwhile, HPV is 
identified as the cause6 of human cervical cancer7 while equally 
one of the most prevalent sexually transmitted infections (STI) in 
the United States8 and worldwide9 too. In about 72.9% of the male 
partners in heterosexually active couples are HPV positive10. 
McNicol and Dodd11 detected HPV even in prostate cancer (PC) 
tissues of adults. Oddly enough, PC has not been documented in 
very young and sexually inactive male12 children. The mortality 
burden of PC has risen to over 360,000 deaths per year13. Some 
risk factors14 for PC like like genetic polymorphisms, family 
history of prostate cancer, race, age, height, physical activity, BMI, 
total energy consumption, intakes of calcium, tomato sauce and 
alpha-linolenic acid and cigarette smoking history are discussed 
in literature while evidence is conflicting15. Especially, several 
different systematic reviews and meta-analysis 16, 17, 18 , 19 , 20 
investigated HPV in relation to PC but opposing reports were 
stated. To clarify the contradictory results of these and other 
investigations, this meta-analysis with updated data has been 
carried out to obtain a more precise picture of the relationship 
between HPV and PC. 
MATERIAL AND METHODS 
Search strategy 
The electronic database PubMed was searched for appropriate 
studies conducted in any country which investigated the 
relationship between HPV and PC. In assessing the shortcomings 
of PubMed, additionally, appropriate review articles and 
references published within the same were checked. 
Study selection 
To be eligible for inclusion, no data access barriers were accepted. 
The titles and abstracts of all the retrieved articles using the 
inclusion criteria were screened. Data extraction was performed 
on included articles.
Ilija Barukcic                                              Journal of Drug Delivery & Therapeutics. 2019; 9(4-s):577-588  
ISSN: 2250-1177                                  [578]                                   CODEN (USA): JDDTAO 
 
Table 1. Flow Diagram of the article selection process. Adopted from PRISMA21, 22 2009. 
1. Identification of records Size Total 
 Records identified by searching in the databases   
  PubMed 45  
  Additional records identified from other sources: 58  
  Review of Yin (n=24) 
Review of Bae (n=30) 
Dillner et al., 1998 
Pourmand et al., 2007 
Schiffmann et al., 2015 
Loeb et al., 2017 
  
 
 
 
 
103 
2. Clean-up of search   
 Inappropriate articles excluded 64  
3. Eligibility   
 Articles evaluated for eligibility 39  
 Articles excluded for various reasons   
 - Self-contradictory data 13  
4. Included   
 Articles included in the meta-analysis  26 
 
Data analysis 
The following data were recorded for analysis. 
The data of the studies analyzed 
The studies reviewed23–44 in this publication investigated the 
conditio per quam relationship between HPV and PC while using 
the highly sensitive PCR technique are presented in more detail by 
a table (Table 2).
 
Table 2. The HPV PCR Studies23–44 considered for a re-analysis of conditio per quam. 
Study Id Year Country Risk Factor Case_
P 
Case_
T 
Con_
P 
Con_T k p-val IOU X² 
(IMP) 
Ibrahim et al. 1992 USA High-risk HPV16/18  PCR 6 24 2 36 0.280224 0.03314108 -0.47 0.28 
Anwar et al. 1992 Japan High-risk HPV16/18/33  
PCR 
28 68 0 10 0.286972 0.00816351 0.23 0.01 
Tu et al. 1994 USA High-risk HPV16/18  PCR 1 43 0 1 0.023255 0.97727272 0.00 0.25 
Moyret-Lalle et al. 1995 France High-risk HPV16/18  PCR 14 27 8 24 0.186630 0.09451920 -0.04 2.56 
Suzuki et al. 1996 Japan High-risk HPV16  PCR 8 51 0 51 0.291729 0.00290368 -0.42 0.03 
Wideroff et al. 1996 USA HPV PCR 7 56 4 42 0.046657 0.23167954 -0.32 1.11 
Terris & Peehl et 
al. 
1997 USA High-risk HPV16/18  PCR 10 53 5 37 0.070692 0.18559829 -0.24 1.35 
Serth et al. 1999 Germany HPV16 PCR 10 47 1 37 0.273334 0.01031477 -0.31 0.02 
Carozzi et al. 2004 Italy High-risk HPV type 14 26 5 25 0.349956 0.01058851 -0.12 1.07 
Leiros et al. 2005 Argentina HPV PCR 17 41 0 30 0.479950 1.46345E-05 -0.18 0.01 
Silvestre et al.  2009 Brasil HPV PCR 2 65 0 6 0.051726 0.837022133 -0.06 0.13 
Martinez-Fierro 
et al.  
2010 Mexico HPV PCR 11 55 4 75 0.226803 0.008602189 -0.46 0.82 
Aghakhani et al. 2011 Iran HPV PCR 13 104 8 104 0.079788 0.095738433 -0.40 2.68 
Salehi and Hadavi 2012 Iran HPV PCR 3 68 0 85 0.158113 0.085627977 -0.54 0.08 
Mokhtari et al. 2013 Iran HPV PCR 3 30 1 90 0.214422 0.044481939 -0.72 0.06 
Whitaker et al. 2013 Australia HPV PCR 7 10 2 10 0.502518 0.032150512 -0.05 0.25 
Michopoulou et 
al. 
2014 Greece HPV PCR 8 50 1 30 0.194069 0.069453811 -0.26 0.03 
Singh et al. 2015 India HPV PCR 39 95 11 55 0.215211 0.004234054 -0.03 2.21 
Huang et al.  2016 China High-risk HPV16/18  PCR 30 75 0 73 0.497451 3.80058E-11 -0.29 0.01 
Atashafrooz et al. 2016 Iran HPV PCR 20 100 8 100 0.172917 0.008230537 -0.36 2.01 
Aydin et al.  2017 Turkey HPV PCR 1 60 0 36 0.079471 0.625 -0.36 0.25 
Zhao et al. 2017 China High-risk HPV16  PCR 48 75 14 80 0.474341 2.10403E-09 -0.12 2.94 
   Total 300 1223 74 1037 0.233234 1.27175E-30  14.444 
            
     N = 2260      
     Alpha 
= 
0.05     
   Degrees of freedom (d. f.)  = 22    
   X² Critical (IMP)  = 33.92
44 
   
   X² Calculated (IMP)  = 14.44
45 
   
   Index of unfairness = -0.29
33 
    
   Case_P: cases, positive; Case_T: cases, total; Con_P: controls, positive; Con_T: controls, total.    
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The studies reviewed23–44 in this publication which investigated the causal relationship between HPV and PC while using the highly 
sensitive PCR technique are presented in more detail by a table (Table 3). 
Table 3. The causal relationship between human papilloma virus and prostate cancer 
Study Id Year Country Risk Factor 
Case_
P 
Case_
T 
Con_
P 
Con_
T 
k p-val (HGD) IOU X²(k) 
Huang et al.  2016 China High-risk HPV16/18  PCR 30 75 0 73 0.497451 3.80058E-11 -0.29 36.62 
Zhao et al. 2017 China High-risk HPV16  PCR 48 75 14 80 0.474341 2.10403E-09 -0.12 34.88 
Leiros et al. 2005 Argentina HPV PCR 17 41 0 30 0.479950 1.46345E-05 -0.18 16.36 
Suzuki et al. 1996 Japan High-risk HPV16  PCR 8 51 0 51 0.291729 0.002903682 -0.42 8.68 
Singh et al. 2015 India HPV PCR 39 95 11 55 0.215211 0.004234054 -0.03 6.95 
Anwar et al. 1992 Japan 
High-risk HPV16/18/33  
PCR 
28 68 0 10 0.286972 0.008163513 0.23 6.42 
Atashafrooz 
et al. 
2016 Iran HPV PCR 20 100 8 100 0.172917 0.008230537 -0.36 5.98 
Martinez-Fie
rro et al.  
2010 Mexico HPV PCR 11 55 4 75 
0.226803
0 
0.008602189 -0.46 6.69 
Serth et al. 1999 Germany HPV16 PCR 10 47 1 37 0.273334 0.010314777 -0.31 6.28 
Carozzi et al. 2004 Italy High-risk HPV type 14 26 5 25 0.349956 0.01058851 -0.12 6.25 
Whitaker et 
al. 
2013 Australia HPV PCR 7 10 2 10 0.502518 0.032150512 -0.05 5.05 
Ibrahim et 
al. 
1992 USA High-risk HPV16/18  PCR 6 24 2 36 0.280224 0.033141089 -0.47 4.71 
Mokhtari et 
al. 
2013 Iran HPV PCR 3 30 1 90 0.214422 0.044481939 -0.72 5.52 
   
Total 241 697 48 672 0.698497 2.95206E-73 -0.49 150 
         
N = 
 
1369 
     
  
  
Alpha = 
 
0.05 
     
  
 
Degrees of freedom (d. f.) = 
 
13 
    
  
  
X² Critical (k) 
=  
22.36 
    
  
  
X² Calculated 
(k) =  
150.37 
    
  
  
p value (k) < 
 
0.00001 
Case_P: cases, positive; Case_T: cases, total; Con_P: controls, positive; Con_T: controls, total.  
 
The Data of the studies not analyzed 
Studies11,45–56 which published data self-contradictory are viewed 
by Table 4 and have not been considered for a review of the 
causal relationship. The reason for the contradiction is highlighted 
by bold letters. However, the majority of these studies (i. e. 
12/20) excluded from the review support the hypotheses that 
HPV is a sufficient condition of PC since X² (IMP) is less than 
3.841458821.
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Table 4. The studies11,45–56 not considered for a re-analysis 
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Marital status and HPV positivity 
The Iranian study and Ghasemian55 et al. provided detailed 
information about the martial status and HPV positivity. The data 
on the relationship between marital status and HPV positivity are 
viewed by the Table 5. The data of study of Pourmand57 et al. are 
self-contradictory and were not considered for a review on this 
topic.
 
Table 5. Marital status55 and HPV positivity 
The study of 
Ghasemian et al. 
 
HPV 
positive 
 
  Yes = +1 No = +0 Total 
Married 
Yes =+1 12  167 179 
No = +0 1 16 17 
 Total 13 183 196 
 
Marital status and prostate cancer 
Data on the relationship between marital status and prostate 
cancer were published by Ghasemian55 et al. are viewed by the 
Table 6. The Iranian data on the relationship between marital 
status and prostate cancer were compared with the data as 
published by the study of Dillner58 et al. The data as published by 
Dillner et al. are viewed by the Table 6 too. The data as provided 
by Schiffmann59 et al. and Huang60 et al. and Loeb61 et al. are not 
appropriate enough and were not considered for a re-analysis.
 
Table 6. Marital status and prostate cancer 
Study  Year N Case_P Case_T Con_P Con_T k p(k) X²(SINE|Bt) X²(SINE|At) p(IOU) p(IOI) 
Dillner et al. 1998 452 154 164 259 288 +0,07 0,05 0,61 2,56 0,27655 0,55088 
Ghasemian et 
al. 
2013 196 27 29 152 167 +0,03 0,278 0,14 0,24 0,06122 0,76531 
 
Statistical Analysis    
All the statistical analyses for the meta-analysis were conducted 
by Microsoft ® Excel ® for Mac ® version 16.2 (181208) software 
(© 2018, Microsoft GmbH, Munich, Germany), with statistical 
significance at P < 0.05. P value, provided with capital letter P, is 
stated as exact number with three decimal places (i.e. P = 0.027). 
The data extracted from the papers were checked for 
self-contradictions and publication bias by the index of 
unfairness62 and by the index of independence. The conditio sine 
qua non relationship, the conditio per quam relationship 6  and the 
mathematical formula of the causal63  relationship were used to 
prove the relationship between HPV and PC for causality. The 
hypergeometric distribution was used to calculate P values. 
Whether a sample distribution observed is identical with a 
theoretical distribution expected was proofed by Pearson’s 
Chi-square goodness of fit test63  too. The applicability of using 
the Pearson chi-squared statistic in cases where the cell 
frequencies of a 2× 2 contingency table are not greater than five is 
widely discussed in literature. The rule of three 63  has been 
applied by the analysis of the study of Whitaker et al.38. The use of 
Yate’s continuity correction in this context is to some extent 
controversary and not essential. 
Additionally, the odds ratio63  (OR), even if severely and 
justifiably criticized and disproved especially by Karl Pearson63  
(1857–1925) and Heron, with a confidence interval of 95% was 
determined. 
Definitions 
Definition 1. (The 2x2 Table) 
A two by two table (also called a contingency table, a notion first 
used by Karl Pearson in 1904) is a useful tool for examining 
relationships between Bernoulli (i. e. Binomial) distributed 
random variables. Consider the case of a Bernoulli distributed 
random variable At occurring/existing et cetera with the 
probability p(At) at the Bernoulli trial (period of time) t. 
Furthermore, consider the case of another Bernoulli distributed 
random variable Bt occurring/existing et cetera with the 
probability p(Bt) at the same Bernoulli trial (period of time) t. Let 
p(at)= p(At  Bt) denote the joint probability distribution of At and 
Bt at the same Bernoulli trial (period of time) t.  The following 
table (Table 7) may show the relationships in more details. 
Table 7. The probabitlities of a contingency table 
  
Conditioned 
B 
 
  Yes = +1 No = +0 Total 
Condition A 
Yes =+1 p(at)  p(bt) p(At) 
No = +0 p(ct) p(dt) p(At) 
 Total p(Bt) p(Bt) 1 
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In this context, it is per definitionem 
  (  )   (  )   (  )     (  )
 (  )   (  )   (  )     (  )
 (  )   (     )     (  )   (  )   (  )
    (  )   (  )   (  )   (  )
    (  )   (  )   (  )   (  )
 (  )   (  )   (  )     (  )   (  )
 (  )    (   (  )   (  ))   (  )   (  )
 (  )   (  )   (  )   (  )   (  )
 (  )   (  )  (   (  ))   (  )     (  )   (  )
 (1) 
 
while +1 denotes the normalized sample space of At and Bt. Under conditions of Einstein’s general theory of relativity,  indicates the cosmological 
“constant”. Einstein’s field equation expressed completely under conditions of classical logic and equally of probability theory simplifies to p(Bt) 
+ p(t) = 1 - p(Bt) + p(t) = p(At) at each point in space-time t while p(at), p(bt), p(ct) and p(dt) may denote equally the probability as associated 
with the four basic fields of nature. Under circumstances were the probability of an event is constant from trial to trial (i. e. Binomial distribution), 
the relationships before simplifies. We obtain some of the relationships per definitionem 
 
      (  )     (  )     (  )
     (  )     (  )     (  )
     (  )     (     )
    (  )
    (  )
    (  )
     (  )     (  )     (  )     (  )
     (  )     (  )     (  )     (  )
 (2) 
The meaning of the abbreviations a, b, c, d, n et cetera are explained by following 2 by 2-table (Table 8). 
Table 8. The sample space of a contingency table 
  
Conditioned B 
(Outcome) 
 
  Yes = +1 No = +0 Total 
Condition A 
(risk factor) 
Yes =+1 a  b A 
No = +0 c d A 
 Total B B n 
 
Definition 2. Index of unfairness 
The probability of an index of unfairness (IOU) is defined as 
 
 (   )          ((
   
 
)  ) (3) 
Definition 3. The Chi Square of an Index of unfairness 
The index of unfairness is grounded on the relationship that N = A + B. Under very appropriate conditions, there should be no deviation of A + B 
from N and the IOU should be equal to 0. The Chi square of an index of unfairness (IOU) is defined as 
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)   (4) 
Definition 4. Index of independence (IOI) 
The probability of an index of independence (IOI) is defined as 
 
 (   )          ((
   
 
)   ) (5) 
Definition 5. The Chi square of an Index of independence 
The index of independence is grounded on the relationship that N = A + B. Under very appropriate conditions, there should be no deviation of A + B 
from N and the IOI should be equal to 0. The Chi square of an index of independence (IOI) is defined as 
 
           (   )  (
(((   )   )  ((   )   )*
 
)   (6) 
Definition 6. Independence 
In the case of independence63 of At and Bt it is generally valid that 
  (     )   (  )   (  ) (7) 
Definition 7. The Mathematical Formula of the Causal Relationship k 
The mathematical formula of the causal relationship k 63  is defined at every single event, at every single Bernoulli trial t, as 
 
 (     )  
 (    )  ( (  )   (  ))
√ (  )  (   (  ))   (  )  (   (  ))
 
 (8) 
where At denotes the cause and Bt denotes the effect. Under some certain circumstances, the chi-square distribution can be applied to 
determine the significance of causal relationship k. Again, it necessary to point out that neither Pearson’s concept of correlation nor Pearson’s 
concept of  is identical with causation. The mathematical formula of the causal relationship k has nothing to do with Pearson’s methods and is 
not identical with correlation. This has been proved many times and is widely discussed in many publications.  
Definition 8. The 95% Confidence Interval of the Causal Relationship k 
The 95% interval for the causal relationship k was calculated by the formula 
 
{ (     )  √
 
 
 
  (     )  √
 
 
 
} (9) 
 
Definition 9. The Chi Square Distribution 
The following critical values of the chi square distribution63  as visualized by Table 9 are used in this publication. 
Table 9. The critical values of the chi square distribution (degrees of freedom: 1) 
  p-Value One sided X² Two sided X² 
The chi square distribution  
0.1000000000 
0.0500000000 
 
1.642374415 
2.705543454 
 
2.705543454 
3.841458821 
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RESULTS 
Theorem 1. Without being married no HPV positivity. 
Claims. 
Null hypothesis: 
Marriage is a necessary condition (a conditio sine qua non) of HPV 
positivity of an Iranian man. In other words, the sample 
distribution of the study analyzed agrees with the hypothetical 
(theoretical) distribution of a necessary condition. 
Alternative Hypothesis: 
Marriage is not a necessary condition (a conditio sine qua non) of 
HPV positivity of an Iranian man. In other words, the sample 
distribution of the study analyzed does not agree with the 
hypothetical (theoretical) distribution of a necessary condition. 
The significance level (Alpha) below which the null hypothesis 
will be rejected is alpha= 0.05. 
Proof.         
The results of the data reviewed and re-analyzed by this article 
which investigated the relationship between marital status and 
HPV positivity of an Iranian man are viewed by the table (Table 
5). The study design of the study of Ghasemian et al. is very 
impressive (p(IOU) = 0,06). The data can be used for causal 
analysis and for the analysis of conditions too. The study analyzed 
was able to provide evidence of a positive cause effect 
relationship. Furthermore, the null-hypothesis: without being 
married no HPV positivity of an Iranian man (Table 10) could not 
be rejected. Marriage is a necessary condition (a conditio sine qua 
non) of HPV positivity of an Iranian man (pSine(Married  HPV 
positive) = 0,995; Chi sq. 1 (SINE) = 0,08; Chi sq. 2 (SINE) = 
0,06; p(IOU) =0,02, k > 0).
 
 
Quod erat demonstrandum. 
Table 10. Statistical analysis of the marital status and HPV positivity 
Statistical  Analysis. p(IOU) = 0,020 p(IOI) = 0,847 
Causal relationship k = +0,009 95 % CI (k): (-0,150  - 0,169) 
  P value (k | HGD) = 0,391 Chi sq.  (k) = 0,017 
  Odds ratio (OR) = 1,150 95 % CI (OR): (0,140 -9,422) 
  p (SINE) = 0,995 Chi sq. 1 (SINE) = 0,077 Chi sq. 2 (SINE) = 0,059 
p (IMP) = 0,148 Chi sq. 1 (IMP) = 152,399 Chi sq. 2 (IMP) = 155,804 
p (SINE ^ IMP) = 0,143 Chi sq. 1 (SINE ^IMP) = 152,476 Chi sq. 2 (SINE ^IMP) = 155,863 
p (EXCL) = 0,939 Chi sq. 1 (EXCL) = 11,077 Chi sq. 2 (EXCL) = 0,804 
 
 
Theorem 2. Without being married no prostate cancer 
Claims. 
Null hypothesis: 
Marriage is a necessary condition (a conditio sine qua non) of 
prostate cancer. In other words, the sample distribution of the 
study analyzed agrees with the hypothetical (theoretical) 
distribution of a necessary condition. 
Alternative Hypothesis: 
Marriage is not a necessary condition (a conditio sine qua non) of 
prostate cancer. In other words, the sample distribution of the 
study analyzed does not agree with the hypothetical (theoretical) 
distribution of a necessary condition. 
The significance level (Alpha) below which the null hypothesis 
will be rejected is alpha= 0.05. 
Proof.         
The results of the re-analyses of the data reviewed by this article 
which investigated the relationship between marital status and 
prostate cancer are viewed by the table (Table 6). Altogether, 
both studies (Finland and Iran) which were meta-analyzed 
provided significant evidence of a conditio sine qua non 
relationship between marital status and prostate cancer. In the 
same respect, the causal relationship k was k > 0. The 
null-hypothesis cannot be rejected. Thus far, the conclusion with 
respect to the studied sample is inescapable, without being 
married no prostate cancer.  
Quod erat demonstrandum. 
Theorem 3. Human papilloma virus is a sufficient condition 
of prostate cancer 
Claims. 
Null hypothesis: 
HPV is a sufficient condition (a conditio per quam) of prostate 
cancer. In other words, the sample distribution of the studies 
analyzed agrees with the hypothetical (theoretical) distribution of 
a sufficient condition. 
Alternative Hypothesis: 
HPV is not a sufficient condition (a conditio per quam) of prostate 
cancer. In other words, the sample distribution of the studies 
analyzed does not agree with the hypothetical (theoretical) 
distribution of a sufficient condition. 
The significance level (Alpha) below which the null hypothesis 
will be rejected is alpha= 0.05. 
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Proof.         
The results of the re-analyses of the data which investigated the 
conditio per quam relationship between HPV and prostate cancer 
are viewed by the table (Table 2). Altogether, if was not possible 
to reject the null-hypothesis: if HPV infection (HPV PCR DNA 
positive) then prostate cancer (X² Calculated (IMP) = 14,4445 < 
X² Critical (IMP) = 33,9244; degrees of freedom: 22; sample 
size n = 2260). HPV is a sufficient condition of PC. 
Quod erat demonstrandum. 
Theorem 4. Human papilloma virus is a cause of prostate 
cancer 
Claims. 
Null hypothesis: 
HPV is not a cause of prostate cancer. In other words, k = 0. 
Alternative Hypothesis: 
HPV is a cause of prostate cancer. In other words, k > 0. 
The significance level (Alpha) below which the null hypothesis 
will be rejected is alpha= 0.05. 
Proof.         
The data which investigated the causal relationship between HPV 
and prostate cancer are viewed by the table (Table 3). Altogether, 
if was necessary to reject the null-hypothesis and to accept the 
alternative hypothesis: HPV is a cause of prostate cancer (X² 
Calculated (k) = 150.37 > X² Critical (k) = 22.36; degrees of 
freedom: 13; sample size n = 1369).  
 
 
 
 
 
Quod erat demonstrandum. 
Theorem 5. Human papilloma virus is the cause of prostate 
cancer 
Claims. 
Null hypothesis: 
HPV is not the cause of prostate cancer. In other words, k = 0. 
Alternative Hypothesis: 
HPV is the cause of prostate cancer. In other words, k > 0. 
The significance level (Alpha) below which the null hypothesis 
will be rejected is alpha= 0.05. 
Proof.         
The study group of Whitaker et al.38 investigated the relationship 
between HPV and prostate cancer and provided data view by 
Table 11. The statistical analysis is illustrated by Table 12. The 
Fisher exact test statistic value is 0.0198 for conditio sine qua non 
relationship and for the conditio per quam relationship. The 
critical value of the conditio sine qua non relationship calculated 
according to the rule of three 63  is pcritical(SINE) = 1- (3/20) = 
0,85. Based on the data of Whitaker et al.38 without HPV no PC and 
equally if HPV then PC. The conclusion is inescapable: HPV is the 
cause of PC. 
Quod erat demonstrandum. 
Table 11. HPV is the cause of PC 
The study of 
Whitaker et al.38 
 PC  
  Yes = +1 No = +0 Total 
HPV 
Yes =+1 7 1 8 
No = +0 3 9 12 
 Total 10 10 20 
 
 
Table 12. The study of Whitaker et al.38 
Statistical  Analysis. p(IOU) = 0,100 p(IOI) = 0,100 
Causal relationship k = +0,612 95 % CI (k): (0,112 -1,112) 
  P value ( k | HGD) = 0,010 Chi sq.  (k) = 7,500 
  Odds ratio (OR) = 21,000 95 % CI (k): (1,777 -248,11) 
  p (SINE) = 0,850 Chi sq. 1 (SINE) = 0,900 Chi sq. 2 (SINE) = 0,750 
p (IMP) = 0,950 Chi sq. 1 (IMP) = 0,100 Chi sq. 2 (IMP) = 0,125 
p (SINE ^ IMP) = 0,800 Chi sq. 1 (SINE ^IMP) = 1,000 Chi sq. 2 (SINE ^IMP) = 0,875 
p (EXCL) = 0,650 Chi sq. 1 (EXCL) = 4,900 Chi sq. 2 (EXCL) = 6,125 
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4. DISCUSSION 
Besides of the multiple advantages of the highly valuable and very 
sensitive polymerase chain reaction64 (PCR) technique, PCR does 
have severe limitations65 too. A key factor is the skill of the 
personnel involved in performing and interpreting the 
investigations.  
Studies analyzed the impact of marital status (single, married, 
divorced/separated, and widowed) on PC with contradictory 
results. The Iranian study of Ghasemian et al. provided data which 
support the hypothesis that being married is a necessary 
condition to become HPV positive. In other words, without being 
married no HPV positivity (pSine(Married  HPV positive) = 
0,995; Chi sq. 1 (SINE) = 0,08; Chi sq. 2 (SINE) = 0,06; p(IOU) 
=0,02, k > 0). The study design is extremely fair (p(IOU) =0,02) 
while the causal relationship is positive but not significant. The 
study of Dillner et al. and of Ghasemian et al. provided data on the 
relationship between the marital status and prostate cancer. Both 
studies support the hypothesis, without being married no PC. 
The study design of Dillner et al. with p(IOU) = 0,28 was a very 
unfair (pSine(Married  PC) =0,978; Chi sq.1 (SINE) =0,61; Chi sq. 
2 (SINE) = 2,56; k > 0). The study design of Ghasemian et al. with 
p(IOU) = 0,06 was a little bit unfair (pSine(Married  PC) =0,989; 
Chi sq. 1 (SINE) =0,14; Chi sq. 2 (SINE) =0,24).  
The studies analyzed provided a very convincing evidence of a 
cause effect relationship between HPV and PC (X² Calculated (k) = 
150.37 > X² Critical (k) = 22.36; degrees of freedom: 13; sample 
size n = 1369). Whitaker et al.38 provided data which support the 
hypothesis that HPV is the cause of PC (P value 0.0198). 
5. CONCLUSION 
HPV is the cause of PC. 
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